Elif ÖZMERT, Orhan DERMAN, Kadriye YURDAKÖK, Belma GİRAY, Murat KIZILGÜN, Pınar ERKEKOĞLU, Erdem DURMAZ

Fitalat teması ile plazma amilaz ve lipaz düzeyleri arasındaki ilişkinin pubertal jinekomasti hastalarında değerlendirilmesi

Amaç: Bu çalışmanın amacı, endokrin bozucu etkileri bilinen di(2-etilhekzil)fitalat (DEHP) ve metaboliti mono (2-etilhekzil) fitalat (MEHP) plazma düzeylerinin yüksek olduğu belirlenen pubertal jinekomasti hastalarında plazma fitalat düzeyleri ile pankreatik lipaz ve a-amilaz düzeyleri arasındaki ilişkinin incelenmesi ve fitalatların pankreas üzerindeki olası etkilerinin değerlendirilmesidir. Gereç ve Yöntem: Çalışma grubu 40 pubertal jinekomasti hastasından oluşmaktadır. Plazma fitalat düzeyleri DEHP ve MEHP mono (2-etikhekzil) Yüksek basınçlı sıvı kromatografisi (high pressure liquid chromatography) kullanılarak belirlenmiştir. Lipaz ve a-amilaz düzeyleri enzimatik kolorimetrik yöntemle ölçülmüştür. İncelenen değişkenler arasındaki ilişki, ilişki katsayısı saptanarak incelenmiştir. Bulgular: Jinekomasti hastalarındaki plazma DEHP ve MEHP düzeyleri, kontrol grubuna oranla önemli düzeyde yüksek bulunmuştur. Alfa-amilaz ve MEHP düzeyleri arasında jinekomasti hastalarında (r=-0,388, p

Evaluation of the correlation between plasma amylase and lipase levels and phthalate exposure in pubertal gynecomastia patients

Aim: The aim of this study was to determine the correlation between plasma phthalate and pancreatic lipase and a-amylase levels in pubertal gynecomastia patients with high plasma levels of di(2-ethylhexyl)phthalate (DEHP) and its metabolite mono (2-ethylhexyl) phthalate (MEHP) which are known endocrine disrupting chemicals and to evaluate the possible effects of phthtalates in pancreas. Material and Method: The study group was composed of 40 pubertal gynecomastia patients. Plasma phthalate levels (Di(2-ethylhexyl)phthalate, DEHP and mono (2-ethylhexyl) phthalate, MEHP) were determined using HPLC. Plasma lipase and a-amylase levels were measured by using enzymatic colorimetric assay. Results: Plasma DEHP and MEHP levels in gynecomatia patients were higher than the control group significantly. Significant negative correlations existed between a-amylase and MEHP levels in gynecomastia (r=-0.388, p

PDF

___

1. Nebesio TD, Pescovitz OH. Part VII: Environmental effects on puberty. The role of endocrine disruptors in pubertal development. In: Walvoord EC, Pescovitz OH, (eds). When Puberty is Precocious: Scientific and Clinical Aspects. New Jersey: Humana Press; 2007; 425-42.
2. Frederiksen H, Skakkebaek NE, Andersson AM. Metabolism of phthalates in humans. Mol Nutr Food Res 2007; 51: 899-911.
3. ATDSR. Toxicological Profile for Diethylphthalate. Department of Health and Human Services, Public Health Service, Agency for Toxic Substances and Disease Registry, Atlanta; USA, 1995.
4. Kai H, Shono T, Tajiri T, Suita S. Long-term effects of intrauterine exposure to mono-n-butyl phthalate on the reproductive function of postnatal rats. J Pediatr Surg 2005; 40: 429–33.
5. National Toxicology Program Center for the Evaluation of Risks to Human Reproduction NTP-CERHR Expert Panel Report NPT-CERHR-DEHP-00 (National Toxicology Program Center for the Evaluation of Risks to Human Reproduction, Washington DC; USA, 2000.
6. Narula HS, Carlson HE. Gynecomastia. Endocrinol Metab Clin North Am 2007; 36: 497-519.
7. Ma NS, Geffner Mitchell E. Gynecomastia in prepubertal and pubertal men. Curr Opin Pediatr 2008; 20: 465-70.
8. Henley DV, Lipson N, Korach KS, Bloch CA. Pubertal gynecomastia linked to lavender and tea tree oils. N Engl J Med 2007; 356: 479-85.
9. Klaunig JE, Babich MA, Baetcke KP, et al. PPARalpha agonist-induced rodent tumors: modes of action and human relevance. Crit Rev Toxicol 2003; 33: 655-780.
10. Ropero AB, Alonso-Magdalena P, García-García E, Ripoll C, Fuentes E, Nadal A. Bisphenol-A disruption of the endocrine pancreas and blood glucose homeostasis. Int J Androl 2008; 31: 194-200.
11. Lott JA. Inflammatory diseases of the pancreas. Crit Rev Clin Lab Sci 1982; 17: 201-28.
12. Pieper-Bigelow C, Strocchi A, Levitt MD. Where does serum amylase come from and where does it go? Gastroenterol Clin North Am 1990; 19: 793-810.
13. Eckfeldt JH, Levitt MD. Diagnostic enzymes for pancreatic disease. Clin Lab Med 1989; 9: 731-43.
14. Durmaz E, Ozmert EN, Erkekoglu P, et al. Plasma phthalate levels in pubertal gynecomastia. Pediatrics 2010; 125: 122-9.
15. Paris I, Ruggieri F, Mazzeo P, Carlucci G. Simultaneous determination of di(2-ethylhexyl) phthalate and mono(2-ethylhexyl) phthalate in human plasma by HPLC. Anal Lett 2003; 36: 2645-54.
16. Miura Y, Naito M, Ablake M, et al. Short-term effects of di-(2-ethylhexyl) phthalate on testes, liver, kidneys and pancreas in mice. Asian J Androl 2007; 9: 199-205.
17. Mocchiutti NO, Bernal CA. Effects of chronic di(2-ethylhexyl) phthalate intake on the secretion and removal rate of triglyceride-rich lipoproteins in rats. Food Chem Toxicol 1997; 35: 1017-21.
18. Venkata NG, Robinson JA, Cabot PJ, Davis B, Monteith GR, Roberts-Thomson SJ. Mono (2-ethylhexyl) phthalate and mono-n-butyl phthalate activation of peroxisome proliferator activated-receptors alpha and gamma in breast. Toxicol Lett 2006; 163: 224-34.
19. Chen C, Xu S, Wang WX, et al. Rosiglitazone attenuates the severity of sodium taurocholate-induced acute pancreatitis and pancreatitis-associated lung injury. Arch Med Res 2009; 40: 79-88.